Breast Biopsy Market Size to Reach USD 6.41 Billion by 2033, Growing at 10.8% CAGR Led by Rising Cancer Incidence

The global breast biopsy market is poised for robust expansion, driven by the increasing prevalence of breast cancer, growing awareness, and rapid advancements in imaging-guided and minimally invasive technologies. According to Straits Research, the market size was valued at USD 2.55 billion in 2024 and is projected to reach USD 6.41 billion in 2033, growing at a CAGR of 10.8% during the forecast period (2025-2033).

Explore more report overview: https://straitsresearch.com/report/breast-biopsy-market

Breast Biopsy Market Growth Driver

One of the primary drivers fueling breast biopsy market expansion is the increasing prevalence of breast cancer globally. As incidence rates climb, the demand for accurate, early diagnostic procedures such as biopsies becomes more urgent. Healthcare systems and oncologists are placing greater emphasis on early detection and definitive tissue diagnosis to guide treatment decisions, thereby leading to a higher volume of biopsy procedures and, in turn, growing demand for related devices and techniques.

Another significant driver is the rapid advancement of imaging modalities and biopsy systems. Improvements in ultrasound, MRI, and stereotactic imaging, combined with next-generation biopsy devices (such as vacuum-assisted systems, automated biopsy guns, and handheld instruments), are enabling more precise, faster, and less invasive sampling. These technological upgrades enhance diagnostic confidence, reduce procedure time, and improve patient comfort, making biopsies more acceptable and feasible in varied clinical settings. Clinicians and patients alike are gravitating toward solutions that balance diagnostic yield with minimal invasiveness, opening new growth avenues for market participants.

Market Segmentation

The breast biopsy market is segmented by product into biopsy needles, biopsy forceps, guidance systems, needle-based biopsy guns, localization wires, and other guidance techniques. Biopsy needles hold the largest share due to their essential role in core and vacuum-assisted biopsy procedures, supported by ongoing design innovations that enhance tissue yield and patient safety. Forceps and localization wires remain vital in guided and surgical biopsy workflows, while imaging and navigation-based guidance systems are gaining momentum as precision and targeting accuracy become central to modern diagnostic practices.

By biopsy type, core needle biopsy remains the standard owing to its ability to extract larger samples, while vacuum-assisted biopsy continues to grow for detecting non-palpable lesions. Liquid biopsy is emerging as a promising non-invasive alternative for molecular profiling and treatment monitoring. Image-guided techniques using ultrasound, MRI, or mammography dominate, with liquid biopsy gaining traction through ctDNA and NGS-based methods. Hospitals and surgical centers lead adoption due to their comprehensive diagnostic capabilities, followed by breast care and imaging centers that are expanding access to specialized diagnostics and personalized cancer screening.

Request a sample report to get more detailed segmentation: https://straitsresearch.com/report/breast-biopsy-market/request-sample

Regional Insights

North America holds the largest share of the global breast biopsy market, driven by advanced healthcare infrastructure, high screening and diagnosis rates, and substantial investment in oncology diagnostics and medical technologies. The region's strong focus on R&D and frequent regulatory approvals for innovative biopsy systems further reinforce its leadership position, with the U.S. serving as a key hub for clinical adoption and technological advancement.

The Asia-Pacific region is poised for the fastest growth, supported by expanding healthcare infrastructure, rising breast cancer incidence, and increasing awareness in emerging economies such as India, China, and South Korea. Europe continues to maintain a solid market presence through established screening programs and strong regulatory support, while Latin America, the Middle East, and Africa are gradually advancing through improved diagnostic capacity and growing collaborations with global medical device manufacturers.

Breast Biopsy Market Key Players

Several leading global companies are shaping the competitive landscape in the breast biopsy sector.

Hologic, Inc.
Danaher Corporation
Becton, Dickinson and Company
QIAGEN
Illumina, Inc.
Merit Medical Systems
Medtronic
Bio-Rad Laboratories
F. Hoffmann-La Roche Ltd
Thermo Fisher Scientific
GE HealthCare

Buy full report: https://straitsresearch.com/buy-now/breast-biopsy-market

Conclusion

The global breast biopsy market is entering a phase of accelerated expansion, backed by significant clinical need, continued innovation in diagnostic tools, and expanding access to breast cancer screening globally. Although challenges such as patient anxiety and procedural discomfort remain, the momentum remains firmly on the side of growth. Market participants that can deliver high accuracy, minimal invasiveness, and cost-effective solutions tailored to local healthcare environments are likely to succeed. As competition intensifies, alliances, R&D investment, and strategic execution will be key differentiators in capturing a share of this rapidly evolving market.

More Related Reports:

Breast Cancer Liquid Biopsy Market: https://straitsresearch.com/report/breast-cancer-liquid-biopsy-market
Breast Implants Market: https://straitsresearch.com/report/breast-implants-market
Breast Pump Market: https://straitsresearch.com/report/breast-pump-market
Breast Reconstruction Market: https://straitsresearch.com/report/breast-reconstruction-market
Breast Augmentation Market: https://straitsresearch.com/report/breast-augmentation-market

Contact Us

Office 515 A, Amanora Chambers,
Amanora Park Town, Hadapsar,
Pune 411028, Maharashtra, India.

+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

About Us

For over a decade, Straits Research has been a trusted partner to more than 2,000 small and large enterprises, empowering senior leaders and decision-makers with actionable intelligence to navigate complex markets. Our structured syndicate reports, published year-round, cover critical sectors such as chemicals, materials, food and beverage, healthcare, pharmaceuticals, automotive, technology, aerospace, and defense. Combined with our custom research tailored to client-specific needs, we deliver insights that drive business progress and informed decision-making.

This release was published on openPR.